MetaCap

InflaRx N.V. (IFRX) vs Atrium Therapeutics (RNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InflaRx N.V. is the larger company by market cap ($153.3 million vs $149.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IFRX+13.04%RNA-53.08%
+211%+71%-69%
Feb 27, 20261 yearNov 20, 2026
IFRX+13.04%RNA-53.08%
+196%+65%-65%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IFRX versus RNA key metrics
MetricIFRXRNA
Share price$1.04$6.92
Market cap$153.26M$149.27M
1-day change-4.59%-0.86%
YTD return+2.97%—
1-year return-11.86%—
5-year return-79.53%—
EPS (TTM)$-0.37$-5.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.95$16.77
52-week low$0.798$6.36
Distance from 52-week high-64.73%-58.74%
Analyst consensusnonestrong_buy
Avg. price target upside+696.15%+217.92%
Average volume868.66K297.20K
Shares outstanding147.37M21.57M
Employees65—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About InflaRx N.V.

IFRX stock →

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Atrium Therapeutics

RNA stock →

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

Health Care · Biotechnology: Pharmaceutical Preparations

IFRX vs RNA FAQ

Which is bigger, InflaRx N.V. or Atrium Therapeutics?

InflaRx N.V. (IFRX) is larger, with a market capitalization of $153.26M compared with $149.27M for Atrium Therapeutics (RNA).

Are InflaRx N.V. and Atrium Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons